Status:
RECRUITING
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
Lead Sponsor:
Upstream Bio Inc.
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease...
Detailed Description
This is a global, multicenter study to assess the efficacy, safety, and tolerability of verekitug in participants with moderate-to-severe COPD. Adult participants are planned to be enrolled and will b...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
July 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2028
Estimated Enrollment :
666 Patients enrolled
Trial Details
Trial ID
NCT06981078
Start Date
July 2 2025
End Date
July 1 2028
Last Update
February 13 2026
Active Locations (325)
Enter a location and click search to find clinical trials sorted by distance.
1
Kern Research Inc.
Bakersfield, California, United States, 93301
2
PulmoCrit Associates
Encino, California, United States, 91436
3
Torrance Clinical Research Institute
Lomita, California, United States, 90717-2101
4
Dream Team Clinical Research
Pomona, California, United States, 91767